Editorial Office "Bulletin of the Academy of Sciences of Moldova. Medical Sciences"
Abstract
47 patients were involved in the research. The use of immune response modifier glucosaminilmuramilpentapeptide (LIASTEN) along with the antimycobacterial therapy resulted in speeding up abacillation in (1.7±0.2) months, dispersion of focal abnormalities and infiltration in (1.5±0.1) months and the cicatrization of destruction cavities in (1.6±0.1) months as compared to the previous indicators. It should be noted that the average treatment duration during the intensive phase might be reduced by (1.9±0.3) months
